Introduction
============

The leishmaniases consist of a wide spectrum of diseases caused by more than 20 different species of the protozoa belonging to the *Leishmania* genus ([@B108]; [@B10]) and considered by the WHO as an important public health problem and a neglected tropical disease ([@B189]). The infection can generate several clinical manifestations ranging from cutaneous and mucocutaneous lesions to the lethal VL ([@B10]). The disease is endemic in 98 countries around the world, with the annual incidence for CL estimated to be 0.7--1.2 million and 0.2--0.4 million for VL ([@B5]). *Leishmania* has a dimorphic life cycle alternating between the foregut and proboscis (stomodeal valve) of the sand fly (*Phlebotomus* in Africa, Europe and Asia and *Lutzomyia* in the Americas). The replicative procyclic promastigotes form (foregut) differentiates to the infective metacyclic promastigotes and migrates to the insect stomodeal valve. The amastigote forms appear in the interior of the phagolysosomal compartment in the mammalian host macrophage ([@B147]; [@B168]).

Since the 1970's, [L]{.smallcaps}-arginine has been described as an essential amino acid for *Leishmania* promastigote cultivation and growth ([@B91]; [@B163]; [@B164]). Later, [L]{.smallcaps}-arginine was also described as essential for *Leishmania* amastigotes survival and defining the fate of the infection in the host-parasite interaction ([@B183]; [@B184]). As [L]{.smallcaps}-arginine cannot be synthesized *de novo* ([@B95]), the parasite developed complex mechanisms to take up this amino acid by specific transporters and control [L]{.smallcaps}-arginine availability ([@B41]; [@B64]; [@B7]). This amino acid is the precursor in the synthesis of proteins, urea, ornithine, citrulline, nitric oxide (NO), creatinine, agmatine, glutamate, proline, putrescine, spermidine and spermine. On the other hand, [L]{.smallcaps}-arginine can be used to produce NO in macrophages, activate the immune response ([@B134]) and promote the parasite killing ([@B146]; [@B97]).

In this review, we will describe the main aspects of [L]{.smallcaps}-arginine uptake and metabolism in both parasite and host. Each section will describe the molecule that participate and modulate the main pathways where the amino acid can be found, pointing to possible targets for infection control.

*Leishmania* [L]{.smallcaps}-ARGININE Uptake
============================================

*Leishmania* is auxotrophic for many amino acids, including [L]{.smallcaps}-arginine. Therefore, the parasite has developed a complex and specific machinery to take up the exogenous source necessary for its replication and growth ([@B26]; [@B146]). The control of [L]{.smallcaps}-arginine levels depends on the selective uptake, as well as the intracellular concentration ([@B179]; [@B178]). Plasma membrane permeases, as well as H^+^-pumps are responsible for the arginine uptake ([@B199]; [@B179]; [@B58]; [@B156]; [@B112]; [@B121]; [@B41]; [@B29]). It has been shown that to control the intracellular pool of [L]{.smallcaps}-arginine, glutamate and methionine, *L. amazonensis* is able to sense the external availability of amino acids ([@B28]). Another factor that can regulate the [L]{.smallcaps}-arginine uptake is its consumption by ARG activity. The [L]{.smallcaps}-arginine amount increases in the absence of ARG activity ([@B28]). Also, intracellular amastigotes can scavenge essential amino acids from the phagolysosome ([@B112], [@B113]; [@B111]).

Several studies have described the molecular and functional characteristics of the amino acid permeases (AAP), as a high affinity transporter of [L]{.smallcaps}-arginine in *L. donovani* ([@B199]; [@B200]; [@B83]; [@B3]; [@B58]; [@B156]; [@B41]), *L. amazonensis, L. infantum*, and *L. major* ([@B58]; [@B156]; [@B29]; [@B7]). The *aap3* coding sequence is present in two copies, organized *in tandem*, in the genome of *L. donovani* (3.1 and 3.2 copies) ([@B156]; [@B41]) and in *L. amazonensis* (5.1 and 4.7 copies) ([@B29]). The ORF shows 98% identity between the two copies and 93% identity between *L. donovani* and *L. amazonensis* AAP3 ([@B156]; [@B29]). For *L. donovani*, the 3′UTR is completely different between the two copies ([@B41]). A possible explanation for two copies can be related to the post-transcriptional gene regulation according to the environmental conditions, since the two ORFs are similar. *In silico* analyses in TriTrypDB and GenBank databases has shown *aap3* orthologs in the genome of *L. infantum, L. major, L. mexicana, L. gerbilli, L. tropica, L. turanica, L. panamensis, L. braziliensis*, and *L. aethiopica* ([@B7]).

Ld-AAP3 mediates the uptake of [L]{.smallcaps}-arginine, lysine, histidine, phenylalanine and citrulline, with higher affinity for [L]{.smallcaps}-arginine ([@B83]; [@B156]). It does not promote the eflux of the intracellular [L]{.smallcaps}-arginine ([@B83]). The *N*-methyl + arginine acetate and phospho-[L]{.smallcaps}-arginine compete with [L]{.smallcaps}-arginine uptake indicating a stereo-specific transporter by recognition of both guanidino group and the arginine side chain, while [L]{.smallcaps}-arginine analogs, nitro-[L]{.smallcaps}-arginine methyl ester, *N*-nitro-[L]{.smallcaps}-arginine, aminoguanidine, agmatine and o-arginine do not modify [L]{.smallcaps}-arginine uptake ([@B83]).

Under [L]{.smallcaps}-arginine starvation, *L. donovani* senses the lack of the amino acid availability and responds with rapid upregulation of the expression and activity of Ld-AAP3 ([@B64]). The [L]{.smallcaps}-arginine starvation in *L. donovani* promastigotes, axenic amastigotes or intracellular amastigotes also lead to up-regulation of mitogen-activated protein kinase 2 (MPK2), suggesting that the parasite monitor the [L]{.smallcaps}-arginine availability ([@B64]). In addition, temperature change during promastigote to amastigote differentiation (25°C and 34°C, respectively) alters the amount of the *La-aap3* 5.1 transcript as well as protein expression, the localization profile in the plasma membrane and [L]{.smallcaps}-arginine uptake in *L. amazonensis* promastigotes. However, [@B7] observed no difference in expression of the *La-aap3* 4.7 transcript as opposed to the 5.1 copy, indicating that for *L. amazonensis*, the 5.1 copy of the *aap3* gene is the one presenting the regulatory sequences for modulating the expression under different conditions ([@B7]).

The absence of enzymes involved in the polyamines biosynthesis, such as ARG ([@B28]), ODC or SpdS ([@B41]) reduce [L]{.smallcaps}-arginine uptake in *L. amazonensis* and *L. donovani.* Furthermore, the ARG absence upregulated the amino acid transporter aATP11 ([@B7]). Supplementation of *L. donovani* promastigote culture with putrescine reduced the [L]{.smallcaps}-arginine uptake, but increased the intracellular pool of [L]{.smallcaps}-arginine and did not affect ornithine pool. However, spermidine supplementation, reduced both [L]{.smallcaps}-arginine transport and the intracellular pool and ornithine levels ([@B41]). The absence of ODC activity in parasites submitted to putrescine supplementation reduced the internal pool of [L]{.smallcaps}-arginine and maintained ornithine content, but the absence of SpdS activity reduced the internal pool of both [L]{.smallcaps}-arginine and ornithine ([@B41]). Even with decreased [L]{.smallcaps}-arginine uptake, the absence of ODC and SpdS activities did not effect in abundance of the Ld-AAP3 protein ([@B41]). The absence of ARG activity in *L. amazonensis* promastigotes maintained in a putrescine-containing medium lead to an increase in the internal pool of [L]{.smallcaps}-arginine, reduction in *La-aap3* transcripts and reduction of ornithine levels ([@B28]).

The importance of [L]{.smallcaps}-arginine availability and ARG activity has also been described in intracellular amastigotes from *in vitro* infections with macrophages obtained from different organisms and genetic backgrounds, such as BALB/c and C57BL/6 mice strains and human THP-1-derived macrophages. In *Leishmania*-BALB/c and *Leishmania*-THP-1 macrophage infections, the *La-aap3 5.1* copy is upregulated during the time course of infection with *L. amazonensis* ([@B7]; [@B120]). In contrast, in *Leishmania*-C57BL/6 macrophage infection, *La-aap3 5.1* is not regulated during the time course of infection with or without ARG activity ([@B7]). In the absence of ARG activity, both *La*-*aap3 5.1* and *4.7* copies appear up-regulated after 4 h of *Leishmania*-THP-1 infection. These differential behaviors can be explained by the distinct background of the host that can influence the [L]{.smallcaps}-arginine uptake and/or accumulation ([@B7]). Additionally, the lower availability of [L]{.smallcaps}-arginine in melatonin-treated BALB/c macrophage infected with *L. amazonensis*, maintained the levels of *La-aap3 5.1* and *arg* expression to keep the polyamine supply ([@B99]).

To summarize, *Leishmania* senses the [L]{.smallcaps}-arginine availability depending on its ARG activity. The parasite also modulates the [L]{.smallcaps}-arginine uptake by *aap3* expression or other amino acid transporters ([@B64]; [@B7]). The AAP3 localization in the plasma membrane in *L. donovani* ([@B64]) and *L. amazonensis* ([@B7]) is directly related to this sensing mechanism. In addition, the AAP3 localization in the glycosome indicates a direct transport of the amino acid to this organelle ([@B73]; [@B129]; [@B130]; [@B64]; [@B7]).

*Leishmania* [L]{.smallcaps}-ARGININE Metabolism
================================================

Besides the [L]{.smallcaps}-arginine uptake, *Leishmania* also express enzymes involved in the [L]{.smallcaps}-arginine metabolism, including ARG and ODC, as part of the urea cycle and also, enzymes involved in the polyamines production, such as SpdS and SpmS. Since 1978, urea production has been characterized in many *Leishmania* species, and ARG activity has been highlighted as crucial for supplying ornithine for polyamines production, essential for parasite replication and the establishment of infection ([@B26]; [@B117]). On the other hand, some *Leishmania* species, such as *L. braziliensis*, express other enzymes that produce urea using [L]{.smallcaps}-arginine, arginine deaminase and citrulline hydrolase ([@B196]).

The *Leishmania* pathways involving [L]{.smallcaps}-arginine are demonstrated in the **Figure [1](#F1){ref-type="fig"}**. [L]{.smallcaps}-arginine is hydrolyzed by ARG to produce urea and ornithine in the first step of the polyamine pathway. Then, ornithine is decarboxylated by ODC to produce putrescine, which is substrate for spermidine and spermine production by SpdS and SpmS, respectively, adding an aminopropyl group from decarboxylated *S*-adenosylmethionine (dAdoMet) ([@B192]; [@B16]; [@B144], [@B145]; [@B63]; [@B39]). In addition, *Leishmania* also uses [L]{.smallcaps}-arginine to produce NO and citrulline ([@B57]; [@B152]; [@B28]).

![*Leishmania* [L]{.smallcaps}-arginine metabolism. [L]{.smallcaps}-arginine metabolic pathways in *Leishmania* to produce polyamines as well as the interconnection with glutamate and proline metabolism. [L]{.smallcaps}-arginine supplies citrulline and nitric oxide (NO) production. Ornithine supplies proline, glutamate and putrescine production, as well as the interconvertion of glutamate, proline and ornithine. Putrescine is the first polyamine that can form spermidine and spermine, essential for parasite growth. Spermidine is the substrate for spermine and trypanothione production. ADC, arginine decarboxylase; AOCT, *N*-acetylornithine carbamoyltransferase; AOD, acetylornithine deacetylase; AdoMetDC, adenosylmethionine decarboxylase; ASS, argininosuccinate synthase; G5K, glutamate 5-kinase; G5SDH, glutamate-5-semialdehyde dehydrogenase; GspS, glutathionylspermidine synthase; NOS-like, nitric oxide synthase-like; OAT, ornithine aminotransferase; OCD, ornithine cyclodeaminase; ODC, ornithine decarboxylase; OTA, ornithine transacetylase; OTC, ornithine transcarbamylase; P5CDH, pyrroline-5-carboxylate dehydrogenase; P5CR, pyrroline 5-carboxilate reductase; PRODH, proline dehydrogenase; PR, proline racemase; SGDS, succinylglutamate desuccinylase; SpdS, spermidine synthase; SpmS, spermine synthase and TryS, trypanothione synthase.](fmicb-08-02682-g001){#F1}

ARG is a metalloenzyme that requires two manganese atoms for enzymatic activity and uses a water molecule to attack the [L]{.smallcaps}-arginine substrate ([@B85]; [@B38]). The ARG expression has been used as genus identification and classification tool in parasitic protozoa of Trypanosomatidae family, such as *Leishmania* genus ([@B26]; [@B196]). [@B37] described the molecular characterization of the ARG-encoding gene and its genomic organization in *L. amazonensis, L. major*, and *L. mexicana*.

ARG is compartmentalized in the glycosome of promastigotes and amastigotes, as identified for *L. amazonensis, L. mexicana* and *L. donovani* ([@B73]; [@B129]; [@B146]; [@B130]; [@B38]; [@B98]; [@B40]; [@B24]). The glycosomal localization of ARG is crucial for its activity in amastigotes of *L. amazonensis* and *L. mexicana*, since the mislocation of the enzyme reduced *in vitro* and *in vivo* infectivity, emphasizing the importance of this localization for proper ARG function ([@B146]; [@B98]; [@B97]; [@B24]). In addition, *L. amazonensis* axenic amastigotes present a down-regulated ARG expression when compared to promastigotes ([@B8]). However, an increase of ARG expression in intracellular amastigotes during the time course of BALB/c macrophages infection was observed in *L. amazonensis* ([@B120]). These data reinforce the existence of different modulation of ARG expression under environment conditions, such as axenic cultivation of parasites.

Metabolomic data from *L. amazonensis* promastigotes indicate that the absence of ARG activity increased the levels of the intracellular pool of [L]{.smallcaps}-arginine, citrulline and [L]{.smallcaps}-glutamate 5-semialdehyde and reduced proline, aspartate, ornithine, and putrescine, but spermidine and spermine levels were not altered ([@B28]). RNA-seq data support the idea that by modulating the expression of enzymes involved in consumption and production of metabolites from [L]{.smallcaps}-arginine, *L. amazonensis* is able to surpass the absence of ARG activity ([@B8]).

Despite the lower levels of [L]{.smallcaps}-arginine, starved promastigotes increase the citrulline levels, reduce ornithine and putrescine levels and maintain the production of urea and agmatine. Ornithine can be used to produce citrulline through OTC that catalyzes the reaction between ornithine and carbamoyl phosphate (CP) (**Figure [1](#F1){ref-type="fig"}**). This last compound is produced from bicarbonate/ammonia and ATP (NH~3~/HCO~3~^-^/ATP) through CPS. Furthermore, a lower level of AOD transcripts in *La-*arg^-^ may reduce the conversion of *N2*-acetylornithine in ornithine ([@B28]; [@B8]).

The increase in citrulline levels in *La*-arg^-^ can be due to the conversion of [L]{.smallcaps}-arginine in NO and citrulline via NOS-like activity ([@B55]; [@B56],[@B57]; [@B151]; [@B152]; [@B2]) or the conversion of citrulline via arginine deaminase. There are no reports of any functional activity of *Leishmania* arginine deaminase to produce citrulline from arginine. The sustenance of high level of citrulline can occur via the reduction in transcript levels of arginosuccinate synthase which thereby reduces the conversion of citrulline into argininosuccinate ([@B8]). As [L]{.smallcaps}-arginine cannot be *de novo* synthesized in *Leishmania* ([@B95]), implicating in the control of internal [L]{.smallcaps}-arginine availability by parasite transporters for its survival ([@B107]). Yet, ASS activity converting citrulline to arginosuccinate has been demonstrated. It seems that ASS activity is not related with [L]{.smallcaps}-arginine synthesis, but with important biological functions of arginosuccinate in the establishment of the infection ([@B94]; [@B150]).

Even with the reduction in putrescine levels and SpdS transcripts, the levels of spermidine and spermine are maintained ([@B28]). Spermine supplementation did not rescue ODC knockout *L. donovani*, and spermidine supplementation did not rescue ARG knockout *L. donovani* ([@B24]). These observations show that interconversion of spermine to spermidine and putrescine do not occur, supporting that putrescine and spermidine are critical for the survival and the growth of the parasite ([@B144]; [@B24]).

Spermidine provides the production of trypanothione, an important regulator of intracellular thiol redox balance. Trypanothione also acts in the detoxification of hydroperoxide and other stressing chemical oxidant, via the enzymes glutathionylspermidine synthetase (GspS) and glutathionylspermidine-dependent trypanothione synthetase (TryS) ([@B170]; [@B92]; [@B132]).

[L]{.smallcaps}-arginine can be used to produce agmatine through arginine descarboxylase (ADC) activity and agmatine can be converted in putrescine via agmatinase (**Figure [1](#F1){ref-type="fig"}**). The transcripts of ADC and agmatinase have been described in *L. mexicana* and *L. amazonensis* ([@B48]; [@B8]) and the presence of agmatine in *L. amazonensis* ([@B28]).

[L]{.smallcaps}-arginine is also used by promastigotes of *L. braziliensis, L. chagasi, L. donovani, L. donovani, L. infantum, L. major, L. mexicana* and *L. panamensis* to produce NO ([@B152]). In *L. amazonensis* [L]{.smallcaps}-arginine is used to produce both NO and citrulline ([@B55], [@B56],[@B57]; [@B152]; [@B28]). Furthermore, high levels of NO production correlate with high amounts of the infective metacyclic forms in promastigote culture of *L. amazonensis* ([@B57]). The differentiation to axenic amastigotes elevates the amount of NO in *L. amazonensis* compared to promastigotes ([@B169]). Higher levels of citrulline in absence of ARG activity can be the result of the conversion of [L]{.smallcaps}-arginine to NO and citrulline via NOS-like activity ([@B56],[@B57]; [@B151]; [@B152]; [@B2]). NO concentration defines its biological function and in this case, NO can act in post-translational modifications, such as *S*-nitrosylation and tyrosine nitration ([@B33]; [@B89]; [@B109]; [@B135]). It can also interfere with several biological processes, such as PKC signaling, cytochrome c regulation of caspase-cascade inactivation, protein degradation and control of the redox environment, increasing the resistance to toxicity signals into macrophage ([@B161]; [@B15]; [@B82]; [@B122]; [@B1]; [@B76]). Certainly, NO is important to metacyclogenesis and amastigote differentiation ([@B2]) and more studies are needed to elucidate the role of NO production by promastigotes and amastigotes forms.

Altogether, the internal pool of [L]{.smallcaps}-arginine, ornithine, and putrescine is altered in function of external availability of [L]{.smallcaps}-arginine, even with higher levels of ornithine than [L]{.smallcaps}-arginine and putrescine. ARG and ODC activity, as well as the rate and production capacity of enzymes of the polyamines pathways are linked to the fine-tuning capacity of *Leishmania* to sense the external environment. This way, the changes from the mid-gut of sand fly to phagolysosome of mammalian host cell can be sensed by promastigotes or intracellular amastigotes allowing the maintenance of cellular homeostasis.

In addition, [L]{.smallcaps}-arginine starvation promotes an externalization of phospholipids that bind to Annexin-V signaling the apoptosis-like cell death in *L. donovani*, which could be blocked by [L]{.smallcaps}-arginine, ornithine or putrescine supplementation ([@B107]). The change in the phospholipids externalization occurs during nutrients starvation in promastigote *in vitro* growth curve and in metacyclogenesis ([@B187]; [@B45]) influencing the *Leishmania* infectivity ([@B42]; [@B174]; [@B185]).

*Leishmania* Proline and Glutamate Metabolism
=============================================

[L]{.smallcaps}-arginine is one of the most versatile amino acids. It can be hydrolyzed by ARG to produce ornithine and urea, as well as its interconversion into the amino acids proline and glutamate can improve the polyamines production and enable a multi-metabolic fate during parasite growth and differentiation.

Proline and 1-pyrroline-5-carboxylate (P5C) play multifaceted roles in the cellular physiology of mammalian cells. The proline pathways, to the production of polyamines, include the interconversion between proline and P5C, by proline dehydrogenase (PRODH) and pyrroline 5-carboxylate reductase (P5CR). Proline can act as a redox shuttle being oxidized in mitochondria or, still, linked with other metabolic pathways, as pentose phosphate ([@B131]; [@B86]; [@B191]). In addition, glutamate and its metabolites, such as P5C, [L]{.smallcaps}-glutamyl-P and [L]{.smallcaps}-glutamate 5-semihaldehyde, are multipurpose molecules serving as precursors of [L]{.smallcaps}-proline, [L]{.smallcaps}-ornithine, and [L]{.smallcaps}-arginine. Furthermore, glutamate and its metabolites help to protect cells from nutrient depletion, oxidative stress and tumor stress ([@B181],[@B182]; [@B157]).

Ornithine can form [L]{.smallcaps}-proline via OCD, by a NAD^+^-dependent hydride transfer reaction that culminates in ammonia elimination in mammalian cells. [D]{.smallcaps}-proline can be converted to [L]{.smallcaps}-proline by PR, a reversible reaction. [L]{.smallcaps}-proline form P5C by P5CR. Still, P5C can be converted in [L]{.smallcaps}-proline by PRODH. P5C form glutamate by P5CDH. Ornithine can be interconverted to [L]{.smallcaps}-glutamate-5-semialdehyde (G5S) via OAT. Additionally, glutamate form [L]{.smallcaps}-glutamyl-P via [L]{.smallcaps}-glutamate-5-semialdehyde kinase (G5K), follow by G5SDH producing G5S. And G5S can be interconvert to P5C by hydration reaction ([@B65]; [@B191]). [@B28] found that amino acid starvation increased the intracellular pool of glutamate and methionine and decreased proline, ornithine and putrescine. This metabolite profile correlate with enzyme levels based on the following connections: reduction of proline due to P5C by P5CR and the increase of glutamate levels via conversion of P5C through P5CDH activity. The absence of ARG reduce the level of P5CDH transcripts and increase the amount of P5CR transcript, explaining the consumption of proline to be converted to P5C (**Figure [1](#F1){ref-type="fig"}**) ([@B28]; [@B7]). P5C is consumed to increase the levels of [L]{.smallcaps}-glutamate 5-semialdehyde, as well as the [L]{.smallcaps}-glutamyl-phosphate conversion by G5SDH ([@B28]).

The spermidine and spermine synthesis are not reduced in amino acid starved promastigotes. This fact could be explained by the use of proline and/or glutamate to produce P5C/G5S and subsequently ornithine, citrulline and agmatine, partially helping the production of putrescine via conversion of agmatine by agmatinase to supply spermidine and spermine. In addition, increased levels of methionine can source the *S*-adenosyl [L]{.smallcaps}-methionine (AdoMet) formation through methionine adenosyltransferase that uses ATP. Also, AdoMetDC produces decarboxylated S-adenosyl methionine, an aminopropyl-donor molecule used together with putrescine to form spermidine and spermine.

*Leishmania*--Host Interaction
==============================

In mammals, [L]{.smallcaps}-arginine metabolism can be analyzed at the whole organism level or cellular level. Its biosynthesis can instate inflammation or immune regulation during infections or at physiological steady state, respectively ([@B136]; [@B140]). In the initial steps of *Leishmania* infection, there is neutrophil and monocyte recruitment to the affected tissue leading to macrophage differentiation days after infection. This has implications for the recognition of the parasite, opsonization, phagocytosis and consequent induction of inflammatory response with NO production, ROS and pro-inflammatory responses by the mammal cells. These actions coordinate the innate immune response and parasite killing mechanisms, as showed for *L. amazonensis, L. major* and *L. donovani* ([@B125]; [@B110]). However, *Leishmania* can escape from the anti-leishmanicidal mechanisms of macrophages, leading to amastigote differentiation and proliferation in the phagolysosome of the macrophage ([@B69]). In this evasion, the macrophage arginase (ARG1) is activated to provide substrate for polyamine pathways ([@B69]). The parasite shares the [L]{.smallcaps}-arginine intracellular pool with the macrophage.

Some studies have shown the importance of the PRRs in the initiation of the innate immune response, such as TLRs, that recognizes PAMPs or DAMPs ([@B128]). This recognition has implications on the susceptibility or resistance to *Leishmania* infection through the role of TLRs in the activation of the phagocyte. Recognition by TLRs induced antiparasitic activity and the production of pro-inflammatory cytokines, such as IL-1, IL-6, TNF, IL-12 e IFN-γ ([@B4]; [@B43]; [@B49]; [@B46]), which also could influence the rate of NOS2/ARG1 during infection.

*Leishmania* can induce adaptive immune responses via cytokines produced by T CD4^+^ lymphocytes, which can be either polarized to Th1 or Th2 phenotype. Generally, Th2 cells producing IL-4, IL-10, and IL-13 cytokines are capable of inducing ARG1 activity in murine macrophages, leading to a M2 macrophage phenotype that results in NO reduction. This leads to susceptibility to *L. major, L. amazonensis* and *L. donovani* infection, as observed in BALB/c mice infections ([@B124]; [@B34]; [@B12]; [@B22]; [@B84]; [@B193]). On the other hand, the resistance to infection is associated with Th1 response, with the production of TNF, IL-12 and IFN-γ cytokines and induction of NOS2 expression with consequent NO production resulting in a M1 macrophage functional state, as observed in C57BL/6 mice infection ([@B59]; [@B180]; [@B190]; [@B193]; [@B19]; [@B162]). Besides, the resistance to *L. donovani* infection is related to IL-12 mediated Th1 cells activated via MyD88 ([@B80]; [@B43]; [@B114]). Also, chronic disease is associated to Th2 exacerbation in *L. amazonensis, L. major* and *L. mexicana* infection in BALB/c mice ([@B103]).

In skin biopsies and plasma from patients with diffuse CL patients, higher levels of host ARG1 and ODC were detected as well as anti-inflammatory and/or suppressor factor, prostaglandin E2, IL-10 and TGF-β ([@B115]; [@B52]). Lesions of patients with mucocutaneous leishmaniasis (ML) presents higher levels of IFN-γ and lower levels of IL10R than CL patients, but similar levels of TNF-α and IL-10. The exacerbation of inflammation and cytotoxicity can promote tissue destruction. In this way, in lesions of CL patients, the increased levels of cells producing granzyme B correlates with lesion size and necrotic process ([@B149]). Some *Leishmania* molecules, such as lipophosphoglycan (LPG), seem to repress IL1-α ([@B53]), IL-1-β ([@B74]) and IL-12 ([@B27]; [@B18]; [@B188]) production during infection via TLR2. Indeed, *Leishmania*-LPG regulates negatively the TLR4 signaling via SOCS-1 ([@B123]) and reduces TNF by induction of repressor genes, such as SOCS-1 and SOCS-3 ([@B43]; [@B88]; [@B47]). The increase in [L]{.smallcaps}-arginine uptake and ARG1 activity induces polyamines production, which correlates with the increase of IL-10 and reduction of IL-12 and TNF-α levels in *L. donovani* THP-1-derived macrophages infection ([@B106]).

*Leishmania*--Host Interaction Targeting [L]{.smallcaps}-ARGININE Transport and Metabolism
==========================================================================================

Controlled uptake of nutrients and ions into cells is important to maintain the intracellular homeostasis, metabolic and physiological requirements and adaptation of parasite to a hostile environment. *Leishmania* infection induces both an increase in [L]{.smallcaps}-arginine uptake and its hydrolysis to produce polyamines or the uptake of polyamines themselves by host cells ([@B13]; [@B153]; [@B147]; [@B37], [@B39]; [@B168]; [@B155]), as showed in **Figure [2](#F2){ref-type="fig"}**. In infected macrophages, [L]{.smallcaps}-arginine is a common substrate for host NOS2 and ARG1 resulting in NO and citrulline production leading to parasite eradication or parasite replication via polyamine production, respectively. In addition, there are mechanisms for [L]{.smallcaps}-arginine uptake in both the phagolysosome and parasite membrane. Amastigotes can metabolize the amino acid to produce polyamines and/or can take up polyamines from host macrophage to replicate, also modifying the metabolism of host cell.

![Metabolic fate of [L]{.smallcaps}-arginine in *Leishmania* infected macrophage. [L]{.smallcaps}-arginine uptake in the macrophage occurs mostly through CAT2B transporter. Once inside the macrophage, the amino acid is directed to nitric oxide (NO) or polyamines synthesis. NO is produced through NOS2 activity. Arginase (ARG) activity produces ornithine that is further decarboxylated by ornithine decarboxylase (ODC) producing putrescine, a substrate for spermidine synthase (SpdS) and spermine synthase (SpmS) producing spermidine and spermine, respectively. Some intermediate metabolites may cross phagolysossome and the parasite plasmatic membrane. These transporters have not been described yet. The [L]{.smallcaps}-arginine uptake occurs by amino acid permease 3 (AAP3) over the parasite plasmatic membrane and to glycosome for polyamines production by the parasite.](fmicb-08-02682-g002){#F2}

In mammalian cells, the endogenous synthesis of [L]{.smallcaps}-arginine from proline or glutamate via ornithine is not sufficient to supply the various pathways that need this amino acid as precursor, highlighting the importance of [L]{.smallcaps}-arginine uptake via cationic amino acid transporters (CAT1, CAT2A, CAT2B, CAT3) that differ in affinity to [L]{.smallcaps}-arginine, ornithine, histidine and lysine ([@B32], [@B31]) Therefore, the control of [L]{.smallcaps}-arginine-uptake is an important factor to elicit the macrophage responses against *Leishmania* ([@B101]; [@B78]). Th1 cytokines production, such as TNFα and IFN-γ, induce macrophages to increase [L]{.smallcaps}-arginine uptake mainly via CAT2B and NO production by NOS2 leading to parasite death ([@B67],[@B68]; [@B100]; [@B194],[@B195]; [@B183]). Th2 cytokines also induce CAT2B, however, ARG1 activity deviate [L]{.smallcaps}-arginine to polyamines production, enabling the parasite survival and replication ([@B37], [@B39]; [@B79]; [@B194],[@B195]; [@B183]).

The M1 and M2 type macrophages differ in the induction of CAT2 expression and [L]{.smallcaps}-arginine uptake in BALB/c and C57BL/6 mice. The natural deletion of a region in the CAT2B-coding gene promoter of C57BL/6 macrophages impairs CAT2B expression and reduces [L]{.smallcaps}-arginine uptake, increasing the resistance to *Leishmania* infection compared to BALB/c mice ([@B148]). *L. amazonensis* infection induces the CAT2B, CAT1 and ARG1 expression in BALB/c macrophages enabling the establishment of infection ([@B120]). *L. major* and *L. amazonensis* repress the NOS2 expression and increase ARG1 activity, regulating the *L. major* growth via regulation of polyamines synthesis ([@B44]; [@B93]). The absence of ARG activity in *L. amazonensis* ([@B29]; [@B98]; [@B8]; [@B120]), *L. donovani* ([@B24]), *L. mexicana* ([@B146]) and *L. major* ([@B146]; [@B138]) reduced the infectivity. Infection with *La-*arg^-^ reduces the levels of CAT2B, CAT1 and ARG1 and allows the expression of NOS2 and NO production in BALB/c macrophages, thereby reducing the infectivity ([@B98]; [@B120]). In *L. amazonensis* ([@B98]; [@B120]) and *L. mexicana* ([@B54]) the absence of ARG activity reduces infectivity via NO overproduction by host macrophages, but not in *L. major* ([@B118]). In addition, the treatment of macrophages with the hormone melatonin, blocks [L]{.smallcaps}-arginine uptake via reduction of CAT2B and CAT1 expression, leading to a mild reduction of ARG1 but not of NOS2 expression resulting in a reduction of infectivity of *L. amazonensis*. The importance of [L]{.smallcaps}-arginine in the process was shown with the recovered infectivity after putrescine supplementation of parasites treated with melatonin ([@B99]). In concordance, [L]{.smallcaps}-arginine analog supplementation blocked the parasite growth in infected-macrophages ([@B78]; [@B183]).

CAT1 is the transporter with the highest affinity for [L]{.smallcaps}-arginine ([@B75]) and it is constitutively expressed in some tissues. Activation of macrophages from BALB/c with M-CSF, LPS, IFN-γ, IL-10 and IL-4, as well as [L]{.smallcaps}-arginine deprivation, does not modify CAT1 expression ([@B194],[@B195]). Despite this, starvation of mammalian cells increases the stability and translation of *Cat1* mRNA ([@B11]; [@B75]; [@B23]; [@B104]).

Some studies have shown that the CAT2 expression in BALB/c macrophages is independent of [L]{.smallcaps}-arginine availability and ARG1 or NOS2 activity ([@B72]; [@B195]). In contrast, CAT2 expression and [L]{.smallcaps}-arginine uptake in THP-1-derived macrophages and human monocyte-derived macrophages are dependent on [L]{.smallcaps}-arginine availability and host arginase activity ([@B106]). In addition, the blocking of CAT2 reduces the [L]{.smallcaps}-arginine uptake in *L. donovani*-infected macrophages leading to ARG regulation and decrease of ornithine, spermidine, citrulline and NO levels ([@B194]; [@B106]). Indeed, signals for activation and proliferation of macrophages increase CAT2 levels and [L]{.smallcaps}-arginine uptake ([@B195]). Despite this, spermidine and spermine suppress CAT2B and NOS2 levels and [L]{.smallcaps}-arginine uptake in rat alveolar macrophages ([@B116]) and inhibit NOS2 activity in J774 macrophages ([@B166],[@B167]). Cells with high ARG1 activity induce the uptake of large amount of [L]{.smallcaps}-arginine via CAT2. This may mediate the exchange of ornithine via CAT2 triggering/supplementing the neighboring cells ([@B31]). Spermine inhibits the synthesis of IL-1, TNF-α, IL-6, MIP-1α and MIP-1β in LPS-stimulated human peripheral blood mononuclear cells, which is restored by the polyamine analog 1-4-bis 3-aminopropyl-piperazine (BAP) ([@B198], [@B197]).

Functional characterization of *Leishmania* ARG, using knockout parasites revealed that the enzyme is essential for *in vitro* and *in vivo* proliferation of *L. amazonensis* ([@B37]; [@B29]; [@B98]), *L. mexicana* ([@B146]), *L. major* ([@B146]; [@B138]) and *L. donovani* ([@B24]). Arginase null *L. amazonensis* ([@B37]; [@B29]; [@B98]), *L. mexicana* ([@B146]) and *L. major* ([@B146]; [@B138]) presented lower levels of infectivity, with exception of parasite burden in spleen of *L. donovani* infected mice ([@B24]), highlighting differences in ARG role in the infection fate of distinct species.

Evasion of Immune Response Pointing [L]{.smallcaps}-ARGININE Metabolism
=======================================================================

Since polyamines are essential for *Leishmania* growth and NO plays an antiparasitic effect, the activity of ARG1 *versus* NOS2 is a central factor in the immune response leading to host susceptibility or resistance. These enzymes are mutually regulated due to substrate sharing transcriptional and post-transcriptional mechanisms controlling enzyme expression and activity. *Leishmania* parasites are believed to escape from the macrophage killing response by targeting the [L]{.smallcaps}-arginine metabolism, although the molecular mechanisms are not totally understood.

The antiparasitic activity of macrophages could be reduced via inhibition of cytokines and NO, which production is mediated by transcription factors such as NF-κB, AP-1, STAT and CREB, and reduction in PKC activity, calcium influx and ERK dephosphorylation ([@B61], [@B62]; [@B50],[@B51]; [@B69]; [@B127]; [@B19]). *L. major* and *L. amazonensis* amastigotes block the nuclear translocation of NF-κB dimer p50/p65, but increases the dimer p50/p50 translocation, which repress the transcription of pro-inflammatory cytokines ([@B70]; [@B25]), NOS2 and CAT2 ([@B44]) and induces the transcription of IL-10 ([@B70]; [@B25]).

Post-transcriptional regulation by miRNAs has been recently described as an important component of the polyamines/NO pathways modulation in infected macrophages. MicroRNAs are small non-coding RNAs that are capable of binding to complementary 3′ UTR regions of target mRNA, regulating its stability or translation ([@B14]; [@B102]). *L. amazonensis* infection increased the expression of some macrophage miRNAs, such as miR-294 and miR-721. These miRNAs interact with 3′ UTR region of *Nos2* mRNA, reducing the enzyme and NO production. Meanwhile, parasites with no ARG activity reduce the expression of those miRNAs and increased NOS2 and NO production, leading to the control of the infection of BALB/c macrophages ([@B120]). *L. donovani* target Dicer1 (RNAse II member family), that could result in post-transcriptional regulation of host mRNAs/miRNA interactions ([@B60]); *Leishmania*-gp63 cleaved Dicer1 impairing the pre-miR122 processing and maturation to miR-122 preventing the binding to RNA-induced silencing complex (RISC), which guides the interaction with target mRNA and leads to gene expression regulation ([@B21]; [@B154]; [@B175]; [@B186]; [@B60]). Furthermore, miR-122 can interact with *Cat1* mRNA 3′UTR regulating its stability and protein levels in stress conditions ([@B23]).

Treatments Targeting [L]{.smallcaps}-ARGININE Metabolism
========================================================

The leishmaniases are neglected tropical diseases affecting primarily underdeveloped regions of the world. They are relatively unattractive for research development, pharmaceutical industry and financial funding. The first-line drug for leishmaniasis treatment recommended by WHO is based on pentavalent antimonial and was described by [@B177]. The leishmaniases chemotherapy is complicated because most of the drugs used are expensive, toxic and require long periods of supervised therapy ([@B119]; [@B77]). The pentavalent antimonial (Glucantime and Pentostan) present several side effects and reports of parasite resistance have been described worldwide ([@B119]). Cases that are unresponsive to antimonial treatment, or patients from Europe or North America are usually treated with amphotericin or PEN, although these drugs also have several side effects ([@B119]; [@B36]). The mechanism of action of pentamidine has been related to the disintegration of the kinetoplast and mitochondria, and a collapse in mitochondrial membrane ([@B35]; [@B176]; [@B17]). In *L. donovani*, pentamidine has been described as a competitive inhibitor of arginine transport ([@B83]) and a non-competitive inhibitor of putrescine and spermidine transport in *L. infantum* ([@B137]), *L. donovani* and *L. mexicana* ([@B16]). In addition, other compounds have been used for leishmaniasis treatment. Miltefosine was the first effective oral drug developed to treat VL. It has been used in India for decades ([@B81]), however, an increase in the failure rate has been reported ([@B165]; [@B141]), possibly by the selection of resistant parasites. Amphotericin B, particularly the liposomal formulation, is also an alternative line for the antimonial treatment and it is associated to binding to the membrane sterol group of *Leishmania* ([@B20]; [@B36]).

Considering the limitations of the currently used chemotherapy and the lack of effective vaccines for the leishmaniases, the identification of new drugs and vaccine approaches for the treatment of leishmaniases is required. A rational strategy for the parasite control can be developed based on the identification of fundamental metabolic pathways of the parasite. New potential drug targets based on molecular and biochemical studies involving the following: protein kinases ([@B126]), glycolytic enzymes ([@B30]), sterol synthesis ([@B172]; [@B105]), purine salvage pathway ([@B171]; [@B96]; [@B9], [@B6]) and polyamine pathway ([@B146]; [@B139]) have been described and could be used in future therapies ([@B158]; [@B160]).

The polyamines pathway could be a promising target, since parasites need the polyamine pathway to replicate and establish the infection in the mammal host ([@B39]). Previous description targeting polyamine-based treatment with l-α-difluoromethylornithine (DFMO) leading to the ODC inhibition in *T. brucei* is described successful against African sleeping sickness ([@B173]). However, the efficacy of DFMO for *Leishmania* is controversial. Previous studies demonstrate the efficacy for *L. donovani, L. infantum* and *L. guyanensis* infections but not for *L. major* and *L. mexicana* ([@B66]; [@B90]). Furthermore, other studies describe the DFMO inefficacy against *Leishmania* ([@B87]).

Other ODC inhibitors have been described, such as 3-aminooxy-1-aminopropane (APA), an isosteric analog of putrescine, effective in *L. donovani* promastigotes and amastigotes ([@B159]). *L. donovani* AdoMetDC was the target for A5′-((Z)-4-amino-2-butenyl)methylamino)-5′-deoxyadenosine (MDL73811) and overexpression of AdoMetDC in *L. donovani* promastigotes conferred resistance to MDL73811, but not to pentamidine, berenil and mitoguazone (MGBG), inhibitors of dAdoMet activity *in vitro* ([@B145]). The overexpression of ODC, AdoMetDC and SpdS in *L. donovani* promastigotes conferred resistance to DFMO, MDL73811, and *n*-butylamine ([@B143]). Interestingly, the resistance to antimonial drugs correlates with ODC overexpression in *L. tarentolae* ([@B71]). Nitric oxide synthase inhibitor [L]{.smallcaps}-NGmonomethylarginine (L-NMMA) reduce the levels of NO and increase the infectivity of *L. infantum* in human macrophages ([@B133]). Controversially, some polyamines analogs or inhibitors could be cytotoxic for host cells because of blocking the polyamines production. In this way, further studies must explore a specific drug for polyamines enzymes of the parasite.

Gene knockout experiments have also been used to demonstrate the importance of some genes in the polyamine pathway as essential for parasite growth ([@B98]; [@B97]). ARG, ODC, AdoMetDC or SpdS null mutant knockout lines have been providing important data on the dependence on supplementation with the substrates for parasite replication in *L. donovani, L. major, L. mexicana* and *L. amazonensis* ([@B98]; [@B97]; [@B24]; [@B8]; [@B142]). In addition, *in vivo* and *in vitro* infections present lower infection index, demonstrating how this pathway can a promisor target chemotherapy.

Another fact that may be considered for new treatment strategy is the fundamental differences between the parasite and its host. A promising target can be the amino acids uptake. As mentioned before, [L]{.smallcaps}-arginine uptake in macrophages is mediated by CAT ([@B32]). In contrast, *Leishmania* has a complex and specific machinery to take up this amino acid. [L]{.smallcaps}-arginine uptake in *Leishmania* is mediated by AAP3 ([@B41]; [@B29]; [@B7]). Since ARG and AAP3 are localized in the plasma membrane and compartmentalized in the glycosome of promastigotes and axenic amastigotes ([@B39]; [@B7]), a strategy to control *Leishmania* infection could be focused on the inhibition of [L]{.smallcaps}-arginine flux by both plasmatic membrane and glycosome of the parasite.

Concluding Remarks
==================

In this review, we elucidate the arginine and polyamine in *Leishmania* infection by both host and parasite. The amino acid availability defines the fate of infection for immune response control or for parasite replication. Activated macrophages produce leishmanicidal molecules, such as NO, that lead to parasite killing, whereas induce ARG expression to parasite replication. These two fates of infection use [L]{.smallcaps}-arginine as a common substrate for their enzymatic activities.
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